Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol

References

• CazzolaMPageCPCalzettaLMateraMGPharmacology and therapeutics of bronchodilatorsPharmacol Rev20126445050422611179
   PubMed Web of Science ®Google Scholar
• QaseemAWiltTJWeinbergerSEDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med201115517919121810710
   PubMed Web of Science ®Google Scholar
• VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med201318734736522878278
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline CentrePulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary CareLondon, UKNational Clinical Guideline Centre2010 Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/EnglishAccessed August 31, 2015
   Google Scholar
• CazzolaMMateraMGBronchodilators: current and futureClin Chest Med20143519120124507846
   PubMed Web of Science ®Google Scholar
• SchwenderCFSundayBRShavelJJr3-[α-(tert-butylamino)methyl]-5-hydroxy-m-xylene-α, α′-diol, a selective bronchodilatorJ Med Chem197417111211154153860
   PubMed Web of Science ®Google Scholar
• BouyssouTHoenkeCRudolfKDiscovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacyBioorg Med Chem Lett2010201410141420096576
   PubMed Web of Science ®Google Scholar
• HandleyDAMorleyJThe pursuit of precision pharmaceuticals: divergent effects of β2 agonist isomersExpert Opin Investig Drugs1998716011616
   PubMedGoogle Scholar
• RamsayCMCowanJFlanneryEBronchoprotective and bronchodilator effects of single doses of (S)-salbutamol, (R)-salbutamol and racemic salbutamol in patients with bronchial asthmaEur J Clin Pharmacol19995535335910456484
   PubMed Web of Science ®Google Scholar
• LötvallJPalmqvistMAnkerstJThe effect of formoterol over 24 h in patients with asthma: the role of enantiomersPulm Pharmacol Ther20051810911315649853
   PubMed Web of Science ®Google Scholar
• BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther2010334536220371707
   PubMed Web of Science ®Google Scholar
• BrownSMBarnesPJDonnellyLEEffect of olodaterol on the relaxation of small airwaysEur Respir J201138308s
   Google Scholar
• CasarosaPKollakIKiechleTFunctional and biochemical rationales for the 24-hour-long duration of action of olodaterolJ Pharmacol Exp Ther201133760060921357659
   PubMed Web of Science ®Google Scholar
• van NoordJASmeetsJJDrenthBM24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPDPulm Pharmacol Ther20112466667221839850
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRBeckEHamiltonALA randomised, placebo-controlled, Phase II, dose-ranging trial of once-daily treatment with olodaterol, a novel long-acting β2-agonist, for 4 weeks in patients with chronic obstructive pulmonary diseaseRespir Med201510959660525829298
   PubMed Web of Science ®Google Scholar
• JoosGFAumannJLCoeckCA randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary diseaseRespir Med201510960661525776199
   PubMed Web of Science ®Google Scholar
• FergusonGTFeldmanGJHofbauerPEfficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014962964524966672
   PubMed Web of Science ®Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studiesInt J Chron Obstruct Pulmon Dis2014969771425045258
   PubMed Web of Science ®Google Scholar
• FeldmanGJBernsteinJAHamiltonAThe 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studiesSpringerplus2014341925187881
   PubMedGoogle Scholar
• LangePAumannJ-LHamiltonAThe 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary diseaseJ Pulm Respir Med201444
   Google Scholar
• GarveyLNiewoehnerDMagderSOne-year safety of olodaterol once daily via Respimat® in patients with GOLD 2–4 chronic obstructive pulmonary disease: results of a pre-specified pooled analysisCOPD20151248449325692310
   PubMedGoogle Scholar
• VestboJAndersonJACalverleyPMAdherence to inhaled therapy, mortality and hospital admission in COPDThorax20096493994319703830
   PubMed Web of Science ®Google Scholar
• ÁghTInotaiAMészárosÁFactors associated with medication adherence in patients with chronic obstructive pulmonary diseaseRespiration20118232833421454953
   PubMed Web of Science ®Google Scholar
• ToyELBeaulieuNUMcHaleJMTreatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costsRespir Med201110543544120880687
   PubMed Web of Science ®Google Scholar
• CazzolaMBeehKMPriceDRocheNAssessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPDPulm Pharmacol Ther201531687825727846
   PubMed Web of Science ®Google Scholar
• PriceDLeeAJSimsEJCharacteristics of patients preferring once-daily controller therapy for asthma and COPD: a retrospective cohort studyPrim Care Respir J20132216116823460035
   PubMedGoogle Scholar
• RossiAKhiraniSCazzolaMLong-acting β2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safetyInt J Chron Obstruct Pulmon Dis2008352152919281071
   PubMedGoogle Scholar
• CazzolaMMateraMGEmerging inhaled bronchodilators: an updateEur Respir J20093475776919720811
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGLötvallJUltra long-acting β2-agonists in development for asthma and chronic obstructive pulmonary diseaseExpert Opin Investig Drugs200514775783
   PubMed Web of Science ®Google Scholar
• CazzolaMCalzettaLMateraMGβ2-adrenoceptor agonists: current and future directionBr J Pharmacol201116341721232045
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCPRoglianiPMateraMGβ2-agonist therapy in lung diseaseAm J Respir Crit Care Med201318769069623348973
   PubMed Web of Science ®Google Scholar
• MateraMGRoglianiPCazzolaMIndacaterol for the treatment of chronic obstructive pulmonary diseaseExpert Opin Pharmacother20151610711525418284
   PubMed Web of Science ®Google Scholar
• RoskellNSAnzuetoAHamiltonAOnce-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterolInt J Chron Obstruct Pulmon Dis2014981382425114521
   PubMed Web of Science ®Google Scholar
• DonohueJFSystematic review comparing LABA, olodaterol, and indacaterol: limitationsInt J Chron Obstruct Pulmon Dis201491331133525525350
   PubMed Web of Science ®Google Scholar
• ChaplinSStriverdi Respimat: once daily LABA for COPDPrescriber2015262526
   Google Scholar
• DeeksEDOlodaterol: a review of its use in chronic obstructive pulmonary diseaseDrugs20157566567325773742
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCLong-acting bronchodilators in COPD: where are we now and where are we going?Breathe201410110120
   Google Scholar
• CazzolaMRoglianiPOraJMateraMGOlodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary diseaseExpert Rev Clin Pharmacol2015852953926294073
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J20154596997925573406
   PubMed Web of Science ®Google Scholar